Pfizer (PFE) stock falls, and its COVID vaccine peers such as Moderna (MRNA) and Novavax (NVAX) also drop as the company ...

Novavax (NVAX) has been struggling to convince the market that its COVID era gains can translate into a durable vaccine business, and the stock’s recent slide reflects those doubts. See our latest ...

Novavax faces plenty of uncertainty related to a deal it signed with a larger company. The biotech's pipeline doesn't look ...

We came across a bullish thesis on Novavax, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ ...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Novavax, Inc. (Symbol: NVAX), where a total volume of 22,231 contracts has been ...

Investors in Novavax, Inc. (Symbol: NVAX) saw new options become available this week, for the July 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Novavax, Inc. reported a 3Q25 EPS loss and declining revenue, but beat revenue expectations and reaffirmed its FY25 guidance, driven by Sanofi partnership milestones. Novavax's heavy reliance on ...

Why is antimony more important currently than ever before? Mr. Evans: Well, it’s not that it’s more important currently, it’s that it’s less available currently. There’s a shortage of antimony ...

Shares of several major vaccine makers lost ground Monday following a report U.S. vaccine approval rules could become stricter.

Worries about regulatory headwinds weighed on vaccine producers on Monday, Dec. 1, 2025, while a chip design software maker got a boost from a partnership with an AI darling.

On Monday, stock markets fought off a weak start to the month of December. The Dow (DJI) lost 427 points to close at 47,289.3 ...